PROTEOMICS IS EXPECTED TO BE ONE of the most active areas in molecular diagnostics and Bio-Rad Laboratories, Inc. has just staked a major claim to a promising proteomic technology. In a transaction announced on August 18, 2006, Bio-Rad will acquire the proprietary proteomics instrument business of Ciphergen Biosystems Inc., which includes the SELDI technology (Surface […]
- "Molecular Diagnostics"
Bio-Rad Buys Ciphergen’s Proteomics Technology
Ciphergen retains exclusive rights to develop clinical diagnostic uses
- By Robert Michel
- > From the Volume XIII No. 12 - September 5, 2006 Issue
